Boise Cascade (NYSE:BCC – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) are both industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Institutional & Insider Ownership
96.2% of Boise Cascade shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 1.4% of Boise Cascade shares are owned by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Boise Cascade and Cyclacel Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Boise Cascade | 1 | 3 | 3 | 0 | 2.29 |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
Boise Cascade has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.
Valuation and Earnings
This table compares Boise Cascade and Cyclacel Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Boise Cascade | $6.40 billion | 0.42 | $132.84 million | $2.95 | 26.18 |
| Cyclacel Pharmaceuticals | $750,000.00 | 6.76 | -$3.00 million | ($3.64) | -0.25 |
Boise Cascade has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Boise Cascade, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Boise Cascade and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Boise Cascade | 1.64% | 5.41% | 3.34% |
| Cyclacel Pharmaceuticals | -118.27% | -31.60% | -27.72% |
Summary
Boise Cascade beats Cyclacel Pharmaceuticals on 12 of the 14 factors compared between the two stocks.
About Boise Cascade
Boise Cascade Company engages in manufacture of wood products and distribution of building materials in the United States and Canada. It operates through two segments, Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber and laminated beams used in headers and beams; I-joists for residential and commercial flooring and roofing systems, and other structural applications; structural, appearance, and industrial plywood panels; and ponderosa pine shop lumber and appearance grade boards. The Building Materials Distribution segment distributes a line of building materials, including oriented strand boards, plywood, and lumber; general line items, such as siding, composite decking, doors, metal products, insulation, and roofing; and engineered wood products. It markets and sells its products to dealers, home improvement centers, wholesalers, specialty distributors, and industrial converters for use in the construction of new residential housing, repair-and-remodeling of existing housing, construction of light industrial and commercial buildings, and other industrial applications. Boise Cascade Company was incorporated in 2004 and is headquartered in Boise, Idaho.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings for Boise Cascade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boise Cascade and related companies with MarketBeat.com's FREE daily email newsletter.
